Christopher Missling - Anavex Life CEO
| AVXL Stock | USD 4.23 0.07 1.63% |
CEO
Dr. Christopher U. Missling, Ph.D., is President, Chief Executive Officer, Secretary, Director of Anavex Life Science Corporationration He was Chief Financial Officer Anavex Life Sciences Corporationration Christopher Missling has over twenty years of healthcare industry experience in big pharmaceutical, biotech industry and investment banking. Most recently, from March 2007 until his appointment by our company, Mr. Missling served as the head of healthcare investment banking at Brimberg Co. in New York, New York. Also, Mr. Missling served as the Chief Financial Officer of Curis, Inc. and ImmunoGen, Inc. since 2015.
| Age | 50 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 630 5th Avenue, New York, NY, United States, 10111 |
| Phone | 844 689 3939 |
| Web | https://www.anavex.com |
Christopher Missling Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Missling against Anavex Life stock is an integral part of due diligence when investing in Anavex Life. Christopher Missling insider activity provides valuable insight into whether Anavex Life is net buyers or sellers over its current business cycle. Note, Anavex Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Anavex Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Missling over six months ago Exercise or conversion by Christopher Missling of 268000 shares of Anavex Life subject to Rule 16b-3 |
Anavex Life Management Efficiency
The company has return on total asset (ROA) of (0.207) % which means that it has lost $0.207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3188) %, meaning that it created substantial loss on money invested by shareholders. Anavex Life's management efficiency ratios could be used to measure how well Anavex Life manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.29. Return On Capital Employed is expected to rise to -0.37 this year. At this time, Anavex Life's Total Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 186.4 M this year, although the value of Other Assets will most likely fall to about 3.7 M.Similar Executives
| Found 14 records | CEO Age | ||
| Maria Maccecchini | Annovis BioInc | 73 | |
| Sean Ianchulev | Eyenovia | N/A | |
| Terren Peizer | Biovie Inc | 57 | |
| John MBA | Novavax | 57 | |
| Stanley Erck | Novavax | 76 | |
| Chen Schor | Madrigal Pharmaceuticals | 41 | |
| Lisa Ricciardi | Cognition Therapeutics | 64 | |
| Thomas MBA | Transcode Therapeutics | 72 | |
| Vimal Mehta | BioXcel Therapeutics | 62 | |
| Brian Lian | Viking Therapeutics | 58 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Michael Morrissey | Exelixis | 63 | |
| Maria Fardis | Iovance Biotherapeutics | 50 | |
| Cuong MBA | Biovie Inc | 58 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.21 |
Anavex Life Sciences Leadership Team
Elected by the shareholders, the Anavex Life's board of directors comprises two types of representatives: Anavex Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anavex. The board's role is to monitor Anavex Life's management team and ensure that shareholders' interests are well served. Anavex Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anavex Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elliot Favus, Director | ||
| CPA CPA, Principal Treasurer | ||
| Christopher Missling, President CEO, CFO, Treasurer, Secretary, Director | ||
| David RPh, Senior Affairs | ||
| Sandra Boenisch, Principal Financial Officer | ||
| Stephan Toutain, Senior Vice President - Operations | ||
| Dr RPh, VP Affairs | ||
| Kun Jin, Head Biostatistics | ||
| MD MPH, Chief Officer | ||
| Athanasios Skarpelos, Director | ||
| Walter MD, Chief Officer | ||
| Walter Kaufmann, Chief Medical Officer | ||
| MS MBA, Senior COO | ||
| Adebayo Laniyonu, Senior Development | ||
| Bernd Metzner, Director | ||
| Steffen Thomas, Director | ||
| Peter Donhauser, Director | ||
| CGA CPA, Principal Treasurer | ||
| Clint Tomlinson, VP Corporate | ||
| Claus Velden, Director | ||
| MBA MS, President, Chairman |
Anavex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anavex Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 208.91 M | ||||
| Shares Outstanding | 82.11 M | ||||
| Shares Owned By Insiders | 3.14 % | ||||
| Shares Owned By Institutions | 32.12 % | ||||
| Number Of Shares Shorted | 22.12 M | ||||
| Price To Earning | (11.03) X | ||||
| Price To Book | 2.60 X | ||||
| EBITDA | (47.5 M) |
Pair Trading with Anavex Life
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anavex Life position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anavex Life will appreciate offsetting losses from the drop in the long position's value.Moving together with Anavex Stock
| 0.79 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against Anavex Stock
| 0.87 | RZLT | Rezolute Trending | PairCorr |
| 0.8 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.78 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.76 | CELC | Celcuity LLC Financial Report 20th of May 2024 | PairCorr |
| 0.67 | ERAS | Erasca Inc Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Anavex Life could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anavex Life when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anavex Life - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anavex Life Sciences to buy it.
The correlation of Anavex Life is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anavex Life moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anavex Life Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anavex Life can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Anavex Stock analysis
When running Anavex Life's price analysis, check to measure Anavex Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anavex Life is operating at the current time. Most of Anavex Life's value examination focuses on studying past and present price action to predict the probability of Anavex Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anavex Life's price. Additionally, you may evaluate how the addition of Anavex Life to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Anavex Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Return On Assets (0.21) | Return On Equity (0.32) |
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.